medigraphic.com

2022, Number 2

<< Back Next >>

Rev Cuba Endoc 2022; 33 (2)

Particularities of insulin resistance in polycystic ovary syndrome

Monteagudo PG, Ovies CG, Rodríguez PB, Álvarez ÁA, Gómez AM, Cabrera GM, Rodríguez MK

Language: Spanish
References: 100
Page:
PDF size: 262.14 Kb.


ABSTRACT

Introduction: Insulin resistance and hyperinsulinemia are frequent in women with polycystic ovary syndrome. This condition is relevant as the main pathogenic factor of the metabolic alterations that accompany the syndrome and because it conditions phenotypes with higher metabolic and reproductive risk.
Objective: To perform a literature review on insulin resistance in polycystic ovary syndrome.
Methods: A state-of-the-art literature review was performed. The particularities of insulin resistance associated with the syndrome and its clinical expression are described.
Conclusions: Insulin resistance is of paramount importance in polycystic ovary syndrome, not only because of its frequency, but also because of the wide spectrum of metabolic and reproductive alterations associated with it. As in other disorders that characterize the syndrome, the specific pathophysiological mechanisms are not entirely clear. However, it is possible to diagnose and treat it in a timely manner, thus preventing complications, some of which are of vital importance. Therefore, and regardless of their body weight, health education from an early age to promote healthy lifestyles, prevention of body overweight and control of other factors that aggravate insulin resistance, including early evaluation of insulin resistance, should be understood as crucial in the management of women with polycystic ovary syndrome.


REFERENCES

  1. Diamanti E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030. DOI: https://doi.org/10.1210/er.2011-10341.

  2. Kiconco S, Tay CT, Rassie KL, Azziz R, Teede HJ, Joham AE. Natural history of polycystic ovary syndrome: A systematic review of cardiometabolic outcomes from longitudinal cohort studies. Clin Endocrinol (Oxf). 2021. DOI: https://doi.org/10.1111/cen.146472.

  3. Osibogun O, Ogunmoroti O, Michos E. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30(7):399-404. DOI: https://doi.org/10.1016/j.tcm.2019.08.010 [ Links ]

  4. Morley L, Tang T, Yasmin E, Norman R, Balen A. Insulin sensitising drugs (metformin, rosiglitazone, pioglitazone, D chiro inositol for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Systematic Review. 2017 [acceso: 01/07/2019]. Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub64.

  5. Kite C, Lahart I, Afzal I, Broom D, Randeva H, Kyrou I, et al. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Systematic Reviews. 2019;8(1):51-79. DOI: https://doi.org/10.1186/s13643-019-0962-35.

  6. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165-74. DOI: https://doi.org/10.2337/diab.38.9.11656.

  7. Stepto NK, Moreno A, McIlvenna LC, Walters KA, Rodgers RJ. Molecular Mechanisms of Insulin Resistance in Polycystic Ovary Syndrome: Unraveling the Conundrum in Skeletal Muscle? J Clin Endocrinol Metab. 2019;104(11):5372-81. DOI: https://doi.org/10.1210/jc.2019-001677.

  8. Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21. DOI: https://doi.org/10.1016/j.cca.2019.11.0038.

  9. Pasquali R. Metabolic Syndrome in Polycystic Ovary Syndrome. Horm Res. 2018;49:114-30. DOI: https://doi.org/10.1159/0004859959.

  10. Dumesic D, Phan J, Leung K, Grogan T, Ding X, Li X, et al. Adipose insulin resistance in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(6):2171-83. DOI: https://doi.org/10.1210/jc.2018-0208610.

  11. Lewandowski KC, Plusajska J, Horzelski W, Bieniek E, Lewinski A. Limitations of insulin resistance assessment in polycystic ovary syndrome. Endocr Connect. 2018;7(3):403-12. DOI: https://doi.org/10.1530/EC-18-002111.

  12. Fenichel P, Rougier C, Hieronimus S, Chevalier N. Which origin for polycystic ovaries syndrome: Genetic, environmental or both? Ann Endocrinol (Paris). 2017;78(3):176-85. DOI: https://doi.org/10.1016/j.ando.2017.04.02412.

  13. Zaki M, Hassan N, El-Bassyouni HT, Kamal S, Basha W, Azmy O. Association of the Pro12Ala Polymorphism with the Metabolic Parameters in Women with Polycystic Ovary Syndrome. Open Access Maced JMedSci. 2017;5(3):275-80. DOI: https://doi.org/10.3889/oamjms.2017.08813.

  14. Ruan Y, Ma J, Xie X. Association of IRS-1 and IRS-2 genes polymorphisms with polycystic ovary syndrome: a meta-analysis. Endocr J. 2012;59(7):601-9. DOI: https://doi.org/10.1507/endocrj.ej11-038714.

  15. Yilmaz M, Yurtçu E, Demirci H, Ergün MA, Ersoy R, Karakoç A, et al. Calpain 10 gene single-nucleotide 44 polymorphism may have an influence on clinical and metabolic features in patients with polycystic ovary syndrome. J Endocrinol Invest. 2009;32(1):13-7. DOI: https://doi.org/10.1007/BF0334567115.

  16. Dunaif A: Perspectives in polycystic ovary syndrome: from hair to eternity. J Clin Endocrinol Metab. 2016;101(3):759-68. DOI: https://doi.org/10.1210/jc.2015-378016.

  17. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43(1):55-9. DOI: https://doi.org/10.1038/ng.73217.

  18. Simonis-Bik AM, Nijpels G, van Haeften TW, Houwing-Duistermaat JJ, Boomsma DI, Reiling E, et al. Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes. 2010;59(1):293-301. DOI: https://doi.org/10.2337/db09-104818.

  19. Goodarzi M, Jones M, Li X, Chua A, García O, Chen Y, et al. Replication of Association of DENND1A and THADA Variants with Polycystic Ovary Syndrome in European Cohort. J Med Genet. 2012;49(2):90-5. DOI: https://doi.org/10.1136/jmedgenet-2011-10042719.

  20. Alizzi Fadia J, Talab Kokaz H, Sharhan Al-Mayah Q. DENND1A and THADA Gene Polymorphism Among Iraqi Women With Polycystic Ovary Syndrome. Inter J of Women's Health and Reprod Sci. 2020 [acceso: 01/07/2019];8:265-71. Disponible en: https://www.sid.ir/en/journal/ViewPaper.aspx?id=77596520.

  21. Bao S, Cai JH, Yang SY, Ren Y, Feng T, Jin T, et al. Association of DENND1A Gene Polymorphisms with Polycystic Ovary Syndrome: A Meta-Analysis. J Clin Res Pediatr Endocrinol. 2016;8(2):135-43. DOI: https://doi.org/10.4274/jcrpe.225921.

  22. Zhu YN, Zhang YT, Liu Q, Shen SM, Zou X, Cao YX, et al. Association analysis between the tag single nucleotide polymorphisms of DENND1A and the risk of polycystic ovary syndrome in Chinese Han women. BMC Med Genet. 2020;21(1):14. DOI: https://doi.org/0.1186/s12881-019-0945-122.

  23. Gao L, Zhang Y, Cui Y, Jiang Y, Wang X, Liu J. Association of the T45G and G276T polymorphisms in the adiponectin gene with PCOS: A meta-analysis. Gynecol Endocrinol. 2012;28(2):106-10. DOI: https://doi.org/10.3109/09513590.2010.50854323.

  24. Tessneer KL, Jackson RM, Griesel BA, Olson AL. Rab5 activity regulates GLUT4 sorting into insulin-responsive and non-insulin-responsive endosomal compartments: a potential mechanism for development of insulin resistance. Endocrinology. 2014;155(9):3315-28. DOI: https://doi.org/10.1210/en.2013-214824.

  25. Yu J, Ding C, Guan S, Wang C. Association of single nucleotide polymorphisms in the RAB5B gene 3'UTR region with polycystic ovary syndrome in Chinese Han women. Biosci Rep. 2019;39(5):BSR20190292. DOI: https://doi.org/10.1042/BSR2019029225.

  26. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. 1997;12(12):2641-8. DOI: https://doi.org/10.1093/humrep/12.12.264126.

  27. Gaasenbeek M, Powell BL, Sovio U, Haddad L, Gharani N, Bennett A, et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab. 2004;89(5):2408-13. DOI: https://doi.org/10.1210/jc.2003-03164027.

  28. Peng HM, Im SC, Pearl NM, Turcu AF, Rege J, Waskell L, et al. Cytochrome b5 Activates the 17,20-Lyase Activity of Human Cytochrome P450 17A1 by Increasing the Coupling of NADPH Consumption to Androgen Production. Biochemistry. 2016;55(31):4356-65. DOI: https://doi.org/10.1021/acs.biochem.6b0053228.

  29. Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, et al. Large-Scale Genome-Wide Meta Analysis of Polycystic Ovary Syndrome Suggests Shared Genetic Architecture for Different Diagnosis Criteria. PLoS Genet. 2018;14(12):e1007813. DOI: https://doi.org/10.1371/journal.pgen.100781329.

  30. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci (USA). 1999;96(15):8573-8. DOI: https://doi.org/10.1073/pnas.96.15.857330.

  31. Mukherjee A, Sidis Y, Mahan A, Raher MJ, Xia Y, Rosen ED, et al. FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci (USA). 2007;104(4):1348-53. DOI: https://doi.org/10.1073/pnas.060796610431.

  32. He J, Liu Q, Yu S, Lei M, Liu J, Di R, et al. Expression and functional analysis of the Follistatin-like 3 (FSTL3) gene in the sheep ovary during the oestrous cycle. Reprod Domest Anim. 2021;56(3):427-36. DOI: https://doi.org/10.1111/rda.1387932.

  33. Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps. Nutrients. 2020;12(8):2401. DOI: https://doi.org/10.3390/nu1208240133.

  34. Jordan CD, Bohling SD, Charbonneau NL, Sakai LY. Fibrillins in adult human ovary and polycystic ovary syndrome: is fibrillin-3 affected in PCOS? J Histochem Cytochem. 2010;58(10):903-15. DOI: https://doi.org/10.1369/jhc.2010.95661534.

  35. Sánchez M, Tena M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020;35:100937. DOI: https://doi.org/10.1016/j.molmet.2020.01.00135.

  36. Polak AM, Adamska A, Krentowska A, Lebkowska A, Hryniewicka J, Adamski M, et al. Body Composition, Serum Concentrations of Androgens and Insulin Resistance in Different Polycystic Ovary Syndrome Phenotypes. J Clin Med. 2020;9(3):732. DOI: https://doi.org/10.3390/jcm903073236.

  37. Baldani D, Skrgatic L, Kasum M, Zlopasa G, Oguic S, Herman M. Altered leptin, adiponectin, resistin and ghrelin secretion may represent an intrinsic polycystic ovary syndrome abnormality. Gynecol Endocrinol. 2019;35:401-5. DOI: https://doi.org/10.1080/09513590.2018.153409637.

  38. Tandon P, Wafer R, Minchin J. Adipose morphology and metabolic disease. J Exp Biol. 2018;221(Pt Suppl 1):jeb164970. DOI: https://doi.org/10.1242/jeb.16497038.

  39. Barber T, Hanson P, Weickert M, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042. DOI: https://doi.org/10.1177/117955811987404239.

  40. Sadrzadeh S, Hui E, Schoonmade L, Painter R, Lambalk C. Birthweight and PCOS: systematic review and meta-analysis. Hum Reprod Open. 2017;2017(2):hox010. DOI: https://doi.org/10.1093/hropen/hox01040.

  41. Kshetrimayum C, Sharma A, Mishra V, Kumar S. Polycystic ovarian syndrome: Environmental/occupational, lifestyle factors; an overview. J Turk Ger Gynecol Assoc. 2019;20(4):255-63. DOI: https://doi.org/10.4274/jtgga.galenos.2019.2018.014241.

  42. Lumme J, Sebert S, Pesonen P, Piltonen T, Järvelin MR, Herzig KH, et al. Vitamin D Levels in Women with Polycystic Ovary Syndrome: A Population-Based Study. Nutrients. 2019;11(11):2831. DOI: https://doi.org/10.3390/nu1111283142.

  43. Dunaif A, Sorbara L, Delson R, Green G. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes. 1993;42(10):1462-8. DOI: https://doi.org/10.2337/diab.42.10.146243.

  44. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod. 2003;18(11):2289-93. DOI: https://doi.org/10.1093/humrep/deg44044.

  45. He F, Li Y. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: a review. J Ovarian Res. 2020;13(1):73. DOI: https://doi.org/10.1186/s13048-020-00670-345.

  46. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96(2):801-10. DOI: https://doi.org/10.1172/JCI11812646.

  47. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol. 2018;19(1):31-44. DOI: https://doi.org/10.1038/nrm.2017.8947.

  48. Vella V, Malaguarnera R, Nicolosi ML, Morrione A, Belfiore A. Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection. Biochim Biophys Acta Mol Cell Res. 2019;1866(11):118522. DOI: https://doi.org/10.1016/j.bbamcr.2019.11852248.

  49. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018;98(4):2133-2223. DOI: https://doi.org/10.1152/physrev.00063.201749.

  50. Uchikawa E, Choi E, Shang G, Yu H, Bai XC. Activation mechanism of the insulin receptor revealed by cryo-EM structure of the fully liganded receptor-ligand complex. Elife. 2019;8:e48630. DOI: https://doi.org/10.7554/eLife.4863050.

  51. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 2006;55(8):2392-7. DOI: https://doi.org/10.2337/db06-039151.

  52. Chang W, Goodarzi M, Williams H, Magoffin D, Pall M, Azziz R. Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. Fertil Steril. 2008;90:2291-7. DOI: https://doi.org/10.1016/j.fertnstert.2007.10.02552.

  53. Cadagan D, Khan R, Amer S. The cal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod Biol. 2016;16:53-60. DOI: https://doi.org/10.1016/j.repbio.2015.12.00653.

  54. Corbould A, Kim YB, Youngren JF, Pender C, Kahn BB, Lee A, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab. 2005;288(5):E1047-54. DOI: https://doi.org/10.1152/ajpendo.00361.200454.

  55. Eriksen M, Pørneki AD, Skov V, Burns JS, Beck-Nielsen H, Glintborg D, et al. Insulin resistance is not conserved in myotubes established from women with PCOS. PLoS One. 2010;5(12):e14469. DOI: https://doi.org/10.1371/journal.pone.001446955.

  56. Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A. Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes. 2006;55(3):751-9. DOI: https://doi.org/10.2337/diabetes.55.03.06.db05-045356.

  57. Seow KM, Juan CC, Hsu YP, Hwang JL, Huang LW, Ho LT. Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery. Hum Reprod. 2007;22(4):1003-10. DOI: https://doi.org/10.1093/humrep/del46657.

  58. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab. 2001;281(2):E392-9. DOI: https://doi.org/10.1152/ajpendo.2001.281.2.E39258.

  59. Shukla P, Mukherjee S. Mitochondrial dysfunction: An emerging link in the pathophysiology of polycystic ovary syndrome. Mitochondrion. 2020;52:24-39. DOI: https://doi.org/10.1016/j.mito.2020.02.00659.

  60. Song D, Hong Y, Sung Y, Lee H. Insulin resistance according to ß-cell function in women with polycystic ovary syndrome and normal glucose tolerance. PLoS ONE. 2017;12:e0178120. DOI: https://doi.org/10.1371/journal.pone.017812060.

  61. Wang T, Zhao Z, Xu Y, Qi L, Xu M, Lu J, et al. Insulin Resistance and ß-Cell Dysfunction in Relation to Cardiometabolic Risk Patterns. J Clin Endocrinol Metab. 2018;103(6):2207-15. DOI: https://doi.org/10.1210/jc.2017-0258461.

  62. Gholinezhad M, Gholsorkhtabaramiri M, Esmaeilzadeh S, Ghanbarpour A. Insulin resistance and adverse metabolic profile in overweight/obese and normal weight of young women with polycystic ovary syndrome. Caspian J Intern Med. 2018;9(3):260-7. DOI: https://doi.org/10.22088/cjim.9.3.26062.

  63. Pande AR, Guleria AK, Singh SD, Shukla M, Dabadghao P. ß cell function and insulin resistance in lean cases with polycystic ovary syndrome. Gynecol Endocrinol. 2017;33(11):877-81. DOI: https://doi.org/10.1080/09513590.2017.134216563.

  64. Amato MC, Vesco R, Vigneri E, Ciresi A, Giordano C. Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. J Endocrinol Invest. 2015;38(12):1319-26. DOI: https://doi.org/10.1007/s40618-015-0372-x64.

  65. Monteagudo G, González R, Gómez M, Ovies G, Menocal A, Rodríguez K, et al. Resistencia a la insulina en mujeres con Síndrome de Ovario Poliquístico. Rev Cubana Endocrinol. 2019 [acceso: 10/07/2021];21(2):e179. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532019000200004&lng=es&nrm=iso&tlng=es65.

  66. Zhang B, Wang J, Shen S, Liu J, Sun J, Gu T, et al. Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome. Biomed Res Int. 2018;2018:6869705. DOI: https://doi.org/10.1155/2018/686970566.

  67. Dumesic DA, Akopians AL, Madrigal VK, Ramirez E, Margolis DJ, Sarma MK, et al. Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women. J Clin Endocrinol Metab. 2016;101(11):4178-88. DOI: https://doi.org/10.1210/jc.2016-258667.

  68. Barazzoni R, Gortan Cappellari G, Ragni M, Nisoli E. Insulin resistance in obesity: an overview of fundamental alterations. Eat Weight Disord. 2018;23(2):149-57. DOI: https://doi.org/10.1007/s40519-018-0481-668.

  69. Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2021;95(4):531-41. DOI: https://doi.org/10.1111/cen.1442169.

  70. Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017;30(1):97-105. DOI: https://doi.org/10.1017/S095442241600028770.

  71. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88. DOI: https://doi.org/10.1016/j.fertnstert.2008.06.03571.

  72. Zeng X, Xie Y, Liu Y, Long S, Mo Z. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21. DOI: https://doi.org/10.1016/j.cca.2019.11.00372.

  73. Lin K, Sun X, Wang X, Wang H, Chen X. Circulating Adipokine Levels in Nonobese Women with Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis. Front Endocrinol. 2021;11:537809. DOI: https://doi.org/10.3389/fendo.2020.53780973.

  74. Cardoso NS, Ribeiro VB, Dutra SG, Ferriani RA, Gastaldi AC, Araújo JE, et al. Polycystic ovary syndrome associated with increased adiposity interferes with serum levels of TNF-alpha and IL-6 differently from leptin and adiponectin. Arch Endocrinol Metab. 2020;64(1):4-10. DOI: https://doi.org/10.20945/2359-399700000019774.

  75. Bannigida DM, Nayak SB, Vijayaragavan R. Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome. Arch Physiol Biochem. 2020;126(4):283-6. DOI: https://doi.org/10.1080/13813455.2018.151898775.

  76. Altinkaya S, Nergiz S, Küçük M, Yüksel H. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014;176:168-72. DOI: https://doi.org/10.1016/j.ejogrb.2014.02.02276.

  77. Chang C, Huang S, Hsu Y, Chin T, Soong Y. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Sci Rep. 2019;9:6447. DOI: https://doi.org/10.1038/s41598-019-42061-977.

  78. Wang C, Zhang XY, Sun Y, Hou XG, Chen L. Higher circulating irisin levels in patients with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2018;34(4):290-3. DOI: https://doi.org/10.1080/09513590.2017.139306578.

  79. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf). 2007;67(5):735-42. DOI: https://doi.org/10.1111/j.1365-2265.2007.02954.x79.

  80. Dahan M, Abbasi F, Reaven G. Relationship between surrogate estimates and direct measurement of insulin resistance in women with polycystic ovary syndrome. J Endocrinol Invest. 2019;42:987-93. DOI: https://doi.org/10.1007/s40618-019-01014-980.

  81. Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017;32(12):2515-21. DOI: https://doi.org/10.1093/humrep/dex30881.

  82. Kurl S, Zaccardi F, Onaemo VN, Jae SY, Kauhanen J, Ronkainen K, et al. Association between HOMA-IR, fasting insulin and fasting glucose with coronary heart disease mortality in nondiabetic men: a 20-year observational study. Acta Diabetol. 2015;52(1):183-6. DOI: https://doi.org/10.1007/s00592-014-0615-x82.

  83. Echiburú B, Crisosto N, Maliqueo M, Pérez-Bravo F, de Guevara AL, Hernández P, et al. Metabolic profile in women with polycystic ovary syndrome across adult life. Metabolism. 2016;65(5):776-82. DOI: https://doi.org/10.1016/j.metabol.2016.01.00683.

  84. Ollila MM, West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study. Hum Reprod. 2017;32(2):423-31. DOI: https://doi.org/10.1093/humrep/dew32984.

  85. Lazaridou S, Dinas K, Tziomalos K. Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome. Hormones (Athens). 2017;16(4):373-80. DOI: https://doi.org/10.14310/horm.2002.175785.

  86. Zhu S, Zhang B, Jiang X, Li Z, Zhao S, Cui L, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. FertilSteril. 2019 Jan;111(1):168-77. DOI: https://doi.org/10.1016/j.fertnstert.2018.09.01386.

  87. Kahn CR. The molecular mechanism of insulin action. Annu Rev Med. 1985;36:429-51. DOI: https://doi.org/10.1146/annurev.me.36.020185.00224187.

  88. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes. 2010;59(11):2697-707. DOI: https://doi.org/10.2337/db10-103288.

  89. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. DOI: https://doi.org/10.1007/BF0028088389.

  90. Hrebícek J, Janout V, Malincíková J, Horáková D, Cízek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab. 2002;87(1):144-7. DOI: https://doi.org/10.1210/jcem.87.1.829290.

  91. Mu L, Li R, Lai Y, Zhao Y, Qiao J. Adipose insulin resistance is associated with cardiovascular risk factors in polycystic ovary syndrome. J Endocrinol Invest. 2019;42(5):541-8. DOI: https://doi.org/10.1007/s40618-018-0949-291.

  92. Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2017;40:1-8. DOI: https://doi.org/10.1007/s40618-016-0523-892.

  93. Li L, Zhang J, Zeng J, Liao B, Peng X, Li T, et al. Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome. Int J Mol Med. 2020;45:1409-16. DOI: https://doi.org/10.3892/ijmm.2020.452293.

  94. Federação Brasileira das Associações de Ginecologia e Obstetrícia (FEBRASGO). Síndrome dos ováriospolicísticos. São Paulo: Orientações e Recomendações FEBRASGO; 2018. p. 103 [acceso: 10/07/2021]. Disponible en: https://www.febrasgo.org.br/media/k2/attachments/18Z-ZSndromeZdosZovriosZpolicsticos.pdf94.

  95. Milewicz A, Kudla M, Spaczynski R, Debski R, Meczekalski B, Wielgos M, et al. The polycystic ovary syndrome: a position statement from the Polish Society of Endocrinology, the Polish Society of Gynaecologists and Obstetricians, and the Polish Society of Gynaecological Endocrinology. Endokrynol Pol. 2018;69:328-6. DOI: https://doi.org/10.5603/EP.2018.00495.

  96. Shahin L, Hyassat D, Batieha A, Khader Y, El-Khateeb M, Ajlouni K. Insulin Sensitivity Indices in Patients with Polycystic Ovary Syndrome with Different Body Mass Index Categories. Curr Diabetes Rev. 2020;16(5):483-9. DOI: https://doi.org/10.2174/157339981566619082315122296.

  97. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract. 2005;11(2):126-34. DOI: https://doi.org/10.4158/EP.11.2.12597.

  98. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018;86:33-43. DOI: https://doi.org/10.1016/j.metabol.2017.09.01698.

  99. Le MT, Nguyen VQ, Truong QV, Le DD, Le VNS, Cao NT. Metabolic Syndrome and Insulin Resistance Syndrome among Infertile Women with Polycystic Ovary Syndrome: A Cross-Sectional Study from Central Vietnam. Endocrinol Metab (Seoul). 2018;33(4):447-58. DOI: https://doi.org/10.3803/EnM.2018.33.4.44799.

  100. Yao K, Bian C, Zhao X. Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy (Review) Experimental And Therapeutic Medicine 2017;14:1271-6. DOI: https://doi.org/10.3892/etm.2017.4642100.




2020     |     www.medigraphic.com